Treatments for snakebites already exist and yet the human toll from snakebites is one of the world's biggest hidden health crises. They kill more than 120,000 people each year and leave another 400,000 with life-changing disabilities, mostly in the poorest communities. To prevent this, we want to help make safe, effective and accessible snakebite treatments a reality.
On this page
Why it's important
Every 5 minutes – roughly the time it will take you to read this page – approximately 50 people are bitten by a snake, of whom 25 people will be envenomed (injected with venom), 4 will be permanently disabled and 1 will die.
Snakebites are inevitable, but the resulting deaths and morbidity are not. With prompt access to well-made and well-selected antivenom, even those bitten by the deadliest snakes, from cobras to vipers, should have a good chance of recovery.
Three key problems are preventing this from happening:
- a global antivenom crisis – the world produces less than half of the antivenom it needs, and this only covers 57% of the world’s species of venomous snake
- a lack of research – with limited investment into snakebite, the emerging technologies that might deliver new treatments have not been properly investigated
- a weak regulatory framework – the current lack of regulatory controls is often allowing inappropriate products to be used.
Antivenom is currently the only medicine for treating snakebite and it is made by injecting horses with venom – a 19th-century technology. There are no common production, safety or efficacy standards, which means there is a high risk of antivenom being contaminated and causing adverse reactions.
At present, victims of snakebite must be treated in hospital, where emergency care is provided, often far from the rural settings where they have been bitten. This delay means that treatment is often given too late to save lives and limbs.
An unstable market for snakebite treatments has driven their costs up. This leads to the withdrawal of treatments from the market because poorer communities cannot sustain the price.
Until now, venomous snakebites have never been regarded as a public health priority or as an issue of urgent concern. As a result, government and intergovernmental agencies have been slow to prioritise prevention of snakebites and integration of treatments into health systems.
What we want to achieve
We want to help transform the way in which snakebite treatments are researched and delivered. If successful, this will also serve as a model for other neglected tropical diseases (NTDs). Our ambitions are to:
Bring production of snakebite treatments into the 21st century
We want to modernise antivenom production by enhancing the science and applying technology to make products better, safer and cheaper. We believe this can happen by working with the World Health Organization (WHO), antivenom producers, and other funders and delivery partners to build a regulatory system that gets more effective products to patients more rapidly.
Develop the next generation of treatments
We will kick-start development of new snakebite treatments and antivenoms by generating an evidence base for which treatments work and why. Through a clinical trials network, we want to bring together fresh expertise from different disciplines and overcome regulatory bottlenecks that hinder investment.
Build and sustain snakebite as a global health priority
We will generate evidence about snakebite’s prevalence and economic cost. This information will help to underpin the development of a more robust market and integrate treatments into health systems where snakebites have most impact, particularly in low- and middle-income countries.
Snakebite facts and figures
- 6.8 billion people live within range of venomous snakes, and of these people 750 million live far from health services
- Snakebites kill between 81,000 and 138,000 people every year, mainly in low-income rural communities in Africa, Asia and South America
- 400,000 people are left with a permanent disability, with 6-8 million Disability Adjusted Life Years (DALYs) lost - a toll comparable to prostate cancer, cervical cancer, rheumatoid arthritis, measles and viral hepatitis
- The world produces less than half of the antivenom it needs
- Venom varies widely between snake species but many clinics are not equipped to respond with the correct antivenom
The areas we're focusing on
Although the problem of snakebite is considerable, it is not intractable. Antivenom can be made safe, effective and accessible, and we know how to stimulate the development of novel therapies that will eventually make treatments significantly better.
There is an opportunity to address this health crisis and we want to change the way science, policy and regulation combine to address neglected diseases in the poorest countries.
We are one of the major research funders and are working in partnership with leaders across different sectors to develop new and accessible treatments and antivenoms.
We want to support governments and regulators to develop procurement and clinical guidelines that are based on evidence and driven by local needs. This means collecting reliable data and strengthening surveillance systems to inform better decision-making
Influence and cross-disciplinary advocacy
Snakebite is now recognised as an NTD and the WHO has made it a priority. We also worked closely with the WHO to develop and implement the new WHO roadmap for snakebite envenoming. We want to build on this momentum and urgency and bolster global coordination.
We will build and sustain partnerships with the public and private sectors we need to make a difference.
The team is supported by a scientific advisory board and governed by an internal programme board. If you have any questions about our work, contact firstname.lastname@example.org.